Letrozole
Brand names: Letrozole, Femara
At a glance
- Medicare prescriptions, 2024
- 735,626
- Medicare drug cost
- $16.4M
- Average cost per prescription
- $22.27
- Clinicians who prescribed it
- 13,818
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Femara is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy. First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer. 1.1 Adjuvant Treatment of Early Breast Cancer Femara (letrozole)
From the FDA-approved prescribing information (label dated June 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Hematology & Oncology 47.8%
- Nurse Practitioners 18.4%
- Medical Oncology 18.1%
- Physician Assistants 5.4%
- Internal Medicine 4.5%
- Family Medicine 1.9%
- Gynecologic Oncology 1.0%
- Hematology 0.8%
- General Surgery 0.6%
- Geriatric Medicine 0.4%
- Hospitalist 0.2%
- General Practice 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 19% from 2019 to 2024.
Biggest change by state since 2019
- Minnesota +63%
- Iowa +44%
- Nevada +40%
- Puerto Rico +39%
- Massachusetts +34%
- Connecticut (smallest change) +1%
- South Carolina (smallest change) +4%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Breckenridge Pharmaceutical, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 2.5 mg | yellow round tablet, 6 mm | N L |
Bryant Ranch Prepack
| Strength | Looks like | Imprint |
|---|---|---|
| 2.5 mg | yellow round tablet, 6 mm | N L |
Carnegie Pharmaceuticals LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 2.5 mg | yellow round tablet, 7 mm | CP 139 |
Chartwell Rx, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 2.5 mg | yellow round tablet, 6 mm | 121 YL |
Novartis Pharmaceuticals Corporation
| Strength | Looks like | Imprint |
|---|---|---|
| 2.5 mg | yellow round tablet, 7 mm | FV CG |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.